Advocacy intelligence hub — real-time data for patient organizations
Arcalyst: FDA approved
Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older
R-Pharm International, LLC — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Arcalyst
(rilonacept)Orphan drugKiniksa Pharmaceuticals, Ltd.
12.1 Mechanism of Action Rilonacept is an interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) cytokine trap. Rilonacept blocks IL-1 signaling b...
Mikhail Samsonov
R-Pharm
Emanuele Bizzi
Fatebenefratelli Hospital
Ruggiero Mascolo
Fatebenefratelli Hospital
Silvia Maestroni
Ospedale Papa Giovanni XXIII
Massimo Imazio
Cardiologia
Claire J Peet, BMBCh MRCP
Clinical research fellow